Reason for request
Inclusion on the list of medicines approved for use by hospitals in the new indication: “treatment of multifocal motor neuropathy (MMN)”.
Clinical Benefit
| Substantial |
The actual benefit provided by TEGELINE in this indication is substantial. |
Clinical Added Value
| important |
The Transparency Committee considers that TEGELINE provides a substantial improvement in actual benefit (IAB II) in patients with multifocal motor neuropathy. |
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
z23wSqzSsRZSzanG
